Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
出版年份 2013 全文链接
标题
Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis
作者
关键词
Multiple Sclerosis, Multiple Sclerosis Patient, Expand Disability Status Scale, Natalizumab, Glatiramer Acetate
出版物
PHARMACOECONOMICS
Volume 31, Issue 6, Pages 455-469
出版商
Springer Nature
发表日期
2013-05-03
DOI
10.1007/s40273-013-0063-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association Between Use of Interferon Beta and Progression of Disability in Patients With Relapsing-Remitting Multiple Sclerosis
- (2012) Afsaneh Shirani et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cost-Effectiveness of Cardiac Resynchronization Therapy in the MADIT-CRT Trial
- (2012) KATIA NOYES et al. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
- Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
- (2012) J. Jaime Caro et al. VALUE IN HEALTH
- Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis
- (2012) Stephanie R. Earnshaw et al. Applied Health Economics and Health Policy
- Cost-effectiveness analyses of treatments for multiple sclerosis: Are they clinically relevant?
- (2011) K. A. Smyth NEUROLOGY
- Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study
- (2011) K. Noyes et al. NEUROLOGY
- Costos de la Esclerosis Múltiple en Colombia
- (2011) Martin Romero et al. VALUE IN HEALTH
- Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis
- (2011) Ken O’Day et al. JOURNAL OF MEDICAL ECONOMICS
- A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective
- (2010) Mark Nuijten et al. CLINICAL THERAPEUTICS
- Pharmacoeconomic Considerations in the Treatment of Multiple Sclerosis
- (2010) Jessica Sharac et al. DRUGS
- Comprehensive Primary Care for Older Patients With Multiple Chronic Conditions
- (2010) Chad Boult et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Does Medicare Have an Implicit Cost-Effectiveness Threshold?
- (2010) James D. Chambers et al. MEDICAL DECISION MAKING
- Generating Evidence for Comparative Effectiveness Research Using More Pragmatic Randomized Controlled Trials
- (2010) C. Daniel Mullins et al. PHARMACOECONOMICS
- Using Comparative Effectiveness Research to Inform Policy and Practice in the UK NHS
- (2010) Kalipso Chalkidou et al. PHARMACOECONOMICS
- Regulatory Benefit-Risk Assessment and Comparative Effectiveness Research
- (2010) Louis P. Garrison PHARMACOECONOMICS
- Perspective and Desire in Comparative Effectiveness Research
- (2010) Anthony J. Culyer PHARMACOECONOMICS
- Managed Care Pharmacy Sees Potential of Comparative Effectiveness Research to Improve Patient Care and Lower Costs
- (2010) Judith Cahill et al. PHARMACOECONOMICS
- An Analysis of NICEʼs ‘Restricted’ (or ‘Optimized’) Decisions
- (2010) Phill OʼNeill et al. PHARMACOECONOMICS
- The Economics of Comparative Effectiveness Studies
- (2010) David Meltzer et al. PHARMACOECONOMICS
- The Value of Value of Information
- (2010) Simon Eckermann et al. PHARMACOECONOMICS
- International Comparison of Comparative Effectiveness Research in Five Jurisdictions
- (2010) Adrian R. Levy et al. PHARMACOECONOMICS
- Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition
- (2010) Slobodan Jankovic et al. Vojnosanitetski Pregled
- Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis
- (2009) Evelyn Chiao et al. CURRENT MEDICAL RESEARCH AND OPINION
- What can be learned from open direct comparative trials in multiple sclerosis?
- (2009) Omar Khan JOURNAL OF THE NEUROLOGICAL SCIENCES
- The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions
- (2009) G Kobelt et al. Multiple Sclerosis Journal
- Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy
- (2009) Patricia K Coyle et al. Multiple Sclerosis Journal
- The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?
- (2009) E. C. Klawiter et al. NEUROLOGY
- Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK
- (2009) Ray Gani et al. PHARMACOECONOMICS
- Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a
- (2009) Shien Guo et al. PHARMACOECONOMICS
- Utilities of the EQ-5D
- (2009) Saskia Knies et al. PHARMACOECONOMICS
- Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population
- (2009) Paul Tappenden et al. VALUE IN HEALTH
- International Comparisons in Valuing EQ-5D Health States: A Review and Analysis
- (2009) Richard Norman et al. VALUE IN HEALTH
- Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study
- (2008) S Minden et al. Multiple Sclerosis Journal
- Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
- (2008) G Kobelt et al. Multiple Sclerosis Journal
- Quantitative risk-benefit analysis of natalizumab
- (2008) J. P. Thompson et al. NEUROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now